Jim Simons Tarsus Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$14.75 - $24.62 $112,100 - $187,112	-7,600 Reduced 6.64%	106,900 $1.9 Million
Q2 2023 Aug 11, 2023	BUY	$11.57 - $19.63 $468,585 - $795,015	40,500 Added 54.73%	114,500 $2.07 Million
Q1 2023 May 12, 2023	BUY	$11.92 - $16.27 $100,128 - $136,668	8,400 Added 12.8%	74,000 $930,000
Q4 2022 Feb 13, 2023	SELL	$14.12 - $18.72 $55,068 - $73,008	-3,900 Reduced 5.61%	65,600 $962,000
Q3 2022 Nov 14, 2022	BUY	$14.08 - $18.5 $129,536 - $170,200	9,200 Added 15.26%	69,500 $1.19 Million
Q2 2022 Aug 12, 2022	BUY	$11.08 - $19.08 $668,124 - $1.15 Million	60,300 New	60,300 $880,000

155

40.4M

37.9K

808K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $884M
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.